H5N1 News and Research

Latest H5N1 News and Research

SFDA approves production license for Sinovac's H1N1 vaccine

Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the State Food and Drug Administration (SFDA) has approved the registration application for PANFLU.1, Sinovac's H1N1 vaccine, and has issued Sinovac a production license for this vaccine.

4 Sep 2009

Sinovac Biotech signs marketing agreement with Boryung Pharmaceutical Company

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has signed an agreement with Boryung Pharmaceutical Company Limited, a Korean manufacturer of pharmaceuticals, to collaborate on marketing efforts and possible vaccine supply efforts to the government of South Korea for Sinovac's H1N1 vaccine.

3 Sep 2009

Preliminary lab results of SHBAN hand sanitizer solution announced

BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has received preliminary independent clinical testing of its patented SHBAN™ Hand Sanitizer Solution to demonstrate it kills the H1N1 (Swine) Influenza A virus.

3 Sep 2009

Sinovac to supply its Anflu seasonal flu vaccine to the Beijing Public Health Bureau

Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the Beijing Public Health Bureau has selected Sinovac as one of the four manufacturers to supply Anflu(R), Sinovac's seasonal influenza vaccine, for the benefit of the citizens of Beijing. The Beijing Public Health Bureau completed the bidding process for the purchase of flu vaccines and corresponding services for 2009 on August 26, 2009. The agreement will be executed after the public notice period.

28 Aug 2009

H1N1 virus detected in turkeys

The detection of an H1N1 virus in turkeys in Chile raises concern that poultry farms elsewhere in the world could also become infected with the pandemic flu virus currently circulating in humans, FAO said today.

27 Aug 2009

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies.

27 Aug 2009

Puricore announces closure of its new USD 2.1 million debt facility

PuriCore plc (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today announces that it has closed on a new USD2.1 million debt facility with Republic First Bank.

26 Aug 2009

DAS181 inhibits H5N1 Influenza lung virus infection of human lung tissues

NexBio, Inc. announced today the publication "DAS181 Inhibits H5N1 Influenza Lung Virus Infection of Human Lung Tissues" in the September, 2009 issue of the journal Antimicrobial Agents and Chemotherapy (AAC).

26 Aug 2009

PuriCore reduces operating expenses by 14% in H1 2009 when compared with H1 2008

PuriCore (LSE: PURI), the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today announces its interim results for the six months ending June 30, 2009. An H1 2009 Operating and Financial Report and detailed financial results are available here at PuriCore’s website.

25 Aug 2009

Adamas Pharmaceuticals forges agreement with U.S. Naval Health Research Center for evaluating triple combination antiviral drug

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).

22 Aug 2009

Medicago and Ajanta Pharma forge MoU to commercialize seasonal influenza VLP-based vaccines in India

Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has signed a Memorandum of Understanding ("MOU") with Ajanta Pharma Limited ("Ajanta") to discuss and negotiate an agreement to commercialize Medicago's pandemic and seasonal influenza VLP-based vaccines in India and other territories.

21 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

Norovirus controlled on cruise ship Marco Polo with vaporisation process by Activ8

The cruise ship Marco Polo, whose round-Britain cruise had to be cancelled because hundreds of passengers became ill with the vomiting bug Norovirus, has been totally disinfected by SitexOrbis' revolutionary infection control fogging service in just 5 hours at the Tilbury docks.

19 Aug 2009

Sinovac Biotech announces positive results from clinical trial of H1N1 vaccine

Sinovac Biotech Ltd. announced today positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine. The clinical data unblinding conference was held in Beijing on the afternoon of August 17, 2009. Notably, Sinovac is the first company worldwide to complete clinical trials for the H1N1 vaccine.

19 Aug 2009

Cannabis Science reports on future plans for cannabis drug trials

Cannabis Science, Inc. (OTCBB: CBIS) has announced that it has completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials.

12 Aug 2009

Nanoviricides herpes study discussed on CBS News report

NanoViricides, Inc. (OTC BB: NNVC.OB), reported today that the CBS affiliate TV station WBRZ interviewed Professor K. Gus Kousoulas , PhD, in which he explained the potential implications of the Company’s nanoviricides™ anti-Herpes drug candidates.

12 Aug 2009

H3N2 influenza unlikely to spread between humans

Seeing animals up close is an integral part of experiencing the state and county fairs that take place around the country each summer and fall. And with good hygiene, Kansas State University veterinary experts say fair visitors shouldn't worry about contracting diseases from animals.

11 Aug 2009

Aethlon Medical tests Hemopurifier against H1N1 virus

Aethlon Medical, Inc. today disclosed that researchers have initiated testing of its Hemopurifier(R) as a candidate treatment against the H1N1 Swine Flu Virus. The Hemopurifier(R) is the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream.

10 Aug 2009

H5N1 avian influenza leaves people at increased risk for Parkinson's disease

At least one strain of the H5N1 avian influenza virus leaves survivors at significantly increased risk for Parkinson's disease and possibly other neurological problems later in life, according to new research from St. Jude Children's Research Hospital.

10 Aug 2009

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), has announced that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides™ drug candidates.

10 Aug 2009

H5N1 News and Research

Latest H5N1 News and Research

SFDA approves production license for Sinovac's H1N1 vaccine

Sinovac Biotech signs marketing agreement with Boryung Pharmaceutical Company

Preliminary lab results of SHBAN hand sanitizer solution announced

Sinovac to supply its Anflu seasonal flu vaccine to the Beijing Public Health Bureau

H1N1 virus detected in turkeys

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

Puricore announces closure of its new USD 2.1 million debt facility

DAS181 inhibits H5N1 Influenza lung virus infection of human lung tissues

PuriCore reduces operating expenses by 14% in H1 2009 when compared with H1 2008

Adamas Pharmaceuticals forges agreement with U.S. Naval Health Research Center for evaluating triple combination antiviral drug

Medicago and Ajanta Pharma forge MoU to commercialize seasonal influenza VLP-based vaccines in India

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Norovirus controlled on cruise ship Marco Polo with vaporisation process by Activ8

Sinovac Biotech announces positive results from clinical trial of H1N1 vaccine

Cannabis Science reports on future plans for cannabis drug trials

Nanoviricides herpes study discussed on CBS News report

H3N2 influenza unlikely to spread between humans

Aethlon Medical tests Hemopurifier against H1N1 virus

H5N1 avian influenza leaves people at increased risk for Parkinson's disease

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

Innovation in neuroscience drug discovery - eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

H5N1 News and Research

Latest H5N1 News and Research

Innovation in neuroscience drug discovery - eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in